Clinical Trials Browser

Interventional × Neurofibromatosis 2 × 1 year × Clear all

NCT07420751 2026-02-20

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

Phase NA Recruiting

Neurofibromatosis 2, Hearing Loss

NCT07131722 2026-01-23

Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

Phase 1/2 Not yet recruiting

Neurofibromatosis 2

NCT04374305 2026-01-12

INTUITT-NF2

Phase 2 Active not recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT03406208 2025-12-24

Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing

Phase NA Completed

Schwannomatosis, Behavior, Neurofibromatosis 1, Neurofibromatosis 2, Neurofibromatoses

NCT03079999 2025-12-18

Study of Aspirin in Patients With Vestibular Schwannoma

Phase 2 Active not recruiting

Neuroma, Acoustic, Neurofibromatosis 2

NCT05521048 2025-12-08

Doxycycline in Cutaneous Schwannoma (NF2)

Phase 1/2 Active not recruiting

Neurofibromatosis 2

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Active not recruiting

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT05130866 2025-10-07

POPLAR-NF2

Phase 2/3 Terminated

Neurofibromatosis 2

NCT03095248 2025-04-22

SEL-TH-1601

Phase 2 Terminated

10 enrolled 9 charts

Ependymoma, Glioma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2